| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | Entrez:608 MIM:109545 HGNC:HGNC:11913 Ensembl:ENSG00000048462 AllianceGenome:HGNC:11913 | |
| Description | TNF receptor superfamily member 17 | |||||
| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding | |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | Entrez:55507 MIM:607437 HGNC:HGNC:13310 Ensembl:ENSG00000111291 AllianceGenome:HGNC:13310 | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | G protein-coupled receptor class C group 5 member D | |||||
| GTO ID | GTC3559 |
| Trial ID | NCT05998928 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA|GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA-GPRC5D CAR-T cells |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With R/R MM Who Received Three or More Lines of Therapy |
| Year | 2023 |
| Country | China |
| Company sponsor | Wuhan Union Hospital, China |
| Other ID(s) | BCMA-GPRC5D CAR-T-cells |
| Cohort 1 | |||||||||||
|
|||||||||||